pharma · Asthma · Type 2 Diabetes
AstraZeneca
NovaPharmaNews editorial coverage mentioning AstraZeneca — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 129
- Drugs
- 77
- Patents
- 25
News & analysis
NovaPharmaNews articles mentioning AstraZeneca — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning AstraZeneca — regulatory, clinical, and market analysis.
Datroway Priority Review Fuels Hope for Metastatic Triple-Negative Breast Cancer Patients
The FDA has granted Priority Review to Datroway for the treatment of metastatic triple-negative breast cancer (TNBC) in patients not eligible for immunotherapy. This designation marks a significant step for AstraZeneca and offers a potential new therapeutic avenue for a challenging cancer subtype.
FDA Approves Baxdrostat (Baxfendy) as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension
The FDA has approved AstraZeneca's baxdrostat (Baxfendy), the first-in-class aldosterone synthase inhibitor, for adults with uncontrolled hypertension. This landmark approval offers a new therapeutic option for patients with difficult-to-treat hypertension.
ASCO 2026: European Pharma's Quiet Showing and What AstraZeneca & Roche Must Address
The ASCO 2026 annual meeting presented a subdued landscape for European pharmaceutical giants like AstraZeneca and Roche, highlighting areas where both companies need to intensify their strategic efforts. Despite a quiet conference, significant market dynamics are at play for these oncology leaders.